---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-026398"
form_type: "8-K"
ticker: "DYAI"
cik: "0001213809"
company_name: "DYADIC INTERNATIONAL INC"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:36:11.075909+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dyadic Q2 2024 revenue down 54% YoY to $386k; net loss $2.05M; cash $10.1M

## Summary
- Net loss $2.045M ($0.07/share) vs $2.153M ($0.07) YoY; operating loss $2.043M.
- Cash and securities $10.1M at June 30, 2024, up from $7.3M at Dec 31, 2023.
- Partnered with Proliant Health for animal-free recombinant albumin; $500k initial payment received.
- Joint development with a Top 10 global dairy for food-grade alpha-lactalbumin.
- Avian flu H5 nanoparticle antigen shows high neutralizing antibody titers in animal studies.

## SEC filing metadata
- accession: 0001437749-24-026398
- form_type: 8-K
- ticker: DYAI
- cik: 0001213809
- company_name: DYADIC INTERNATIONAL INC
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213809/000143774924026398/0001437749-24-026398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213809/000143774924026398/dyai20240523_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-026398
- JSON: https://secwatch.observer/filing/0001437749-24-026398.json
- Plain text: https://secwatch.observer/filing/0001437749-24-026398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.